Condition (MeSH)
Non-Radiographic Axial Spondyloarthritis
ClinicalTrials.gov lists 32 trials for Non-Radiographic Axial Spondyloarthritis or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 7.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
32 of the 32 trials are tagged with Non-Radiographic Axial Spondyloarthritis itself; the rest are tagged with a narrower condition beneath it.
When did Non-Radiographic Axial Spondyloarthritis trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 3 |
| 2017 | 3 |
| 2015 | 4 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Non-Radiographic Axial Spondyloarthritis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 9 |
| Phase 4 | 3 |
| Not applicable | 1 |
| Observational | 12 |
How many Non-Radiographic Axial Spondyloarthritis trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 7 |
| Recruiting | 4 |
| Active, not recruiting | 2 |
| Completed | 13 |
| Terminated | 2 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Non-Radiographic Axial Spondyloarthritis trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 7 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2 |
| UCB Biopharma SRL | 2 |
| AbbVie | 1 |
| Amgen | 1 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Non-Radiographic Axial Spondyloarthritis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| vilamakitug | 1 |
| Acemetacin | 1 |
| Certolizumab | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Secukinmab | 5 |
| Bimekizumab regimen 2 iv | 2 |
| 608 | 2 |
| Adalimumab-US | 1 |
| Xeligekimab Injection | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Non-Radiographic Axial Spondyloarthritis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Ankylosing spondylitis | 7 | 1 |
| Appendicitis | 7 | 2 |
| Abortion spontaneous | 4 | 2 |
| Fibroadenoma of breast | 4 | 2 |
| Osteoarthritis | 4 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Non-Radiographic Axial Spondyloarthritis? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. | Annals of the rheumatic diseases | 2024 | Yes |
| Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. | RMD open | 2024 | Yes |
| Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. | Annals of the rheumatic diseases | 2023 | Yes |
| Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial. | The Journal of rheumatology | 2023 | Yes |
| Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK). | Rheumatology (Oxford, England) | 2023 | Yes |
Showing 5 of 11 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.